In addition, CD11b blockade as well as T cell depletion compromised the tumor growth-reducing effects (Fig. 5 A-C) and animal survival-enhancing of navitoclax and venetoclax against TC1 lung cancers (Fig. 5 D). Here, ITGAM is linked to lung carcinoma.